Clinical trials: Histological Response
Carcinoma, Renal Cell
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to…
- Trial name
- ATILA (NCT03916458)
- Where
- 31 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Pfizer
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular Response in Newly Diagnosed Patients with…
- Trial name
- IDEAL-E (NCT02421926)
- Testing
- IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)
- Where
- 12 sites in South Korea
- Sponsor
- Asan Medical Center
Neuroendocrine Tumors
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans.
- Trial name
- NCT06448208
- Testing
- positron emission tomography (PET) scans
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma for patients who have received at least one prior therapy.
- Trial name
- NCT00128921
- Testing
- VELCADE™
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Arkansas
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non Small Cell Lung Cancer
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- CHECK'UP (NCT03412058)
- Testing
- Biopsy
- Where
- 19 sites in France
- Volunteers
- 152 people
- Sponsor
- UNICANCER
Imatinib Therapy Response, Gastrointestinal Stromal Tumor (GIST)
Hyperpolarized MRI for GIST on Imatinib
Conventional imaging methods, such as CT and MRI, are limited in evaluating GIST response to imatinib, as they mainly reflect tumor size and fail to capture early metabolic or molecular changes.
- Trial name
- DNP_GIST (NCT07724626)
- Testing
- Hyperpolarized 13C-MRI
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
[18F]-AraG PET Imaging in LA HNSCC
This study will use [18F]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for…
- Trial name
- NCT07168785
- Testing
- [18F]-AraG radiotracer, Chemotherapy, Radiotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
- Trial name
- PROPHETIC (NCT04056247)
- Testing
- Plasma sample collection
- Where
- 41 sites in United States, Germany and 3 more
- Volunteers
- 10,000 people
- Sponsor
- OncoHost Ltd.
Hepatocellular Carcinoma
Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)
The objective of this trial was to evaluate the clinical outcome, treatment toxicity and tumor response of TEA for unresectable HCC.
- Trial name
- NCT01837381
- Testing
- TEA
- Where
- 3 sites in Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
This clinical trial studies potential genetic markers which might be used to predict which patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine.
- Trial name
- NCT01687400
- Testing
- decitabine
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Washington University School of Medicine
Oropharyngeal Squamous Cell Carcinoma
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
Doctors leading this study will give blood tests to head and neck cancer participants during the beginning of chemotherapy treatment (also known as induction therapy) to see if these blood tests can help predict tumor shrinkage…
- Trial name
- NCT04572100
- Testing
- Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
- Trial name
- NCT03712202
- Testing
- Bleomycin, Brentuximab Vedotin, Dacarbazine
- Where
- 17 sites in United States
- Volunteers
- 159 people
- Sponsor
- City of Hope Medical Center
Metastatic Malignant Melanoma
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
This multicenter, retrospective observational study aims to identify clinical, pathological, and molecular factors associated with prognosis and treatment response in patients with metastatic malignant melanoma.
- Trial name
- MEL-CARE (NCT07256184)
- Testing
- Systemic Therapy for Metastatic Melanoma
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 232 people
- Sponsor
- Ankara Etlik City Hospital
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Melanoma, Stage IA Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
- Conditions
- Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma
- Trial name
- NCT00003895
- Testing
- HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis
The purpose of this study is to assess the efficacy of Radiofrequency ablation (RFA) and percutaneous acetic acid ablation (PAI) in the management of small hepatocellular carcinoma (HCC) in patients of cirrhosis of liver.
- Trial name
- NCT01438437
- Testing
- PAI, RFA
- Where
- India
- Volunteers
- 54 people
- Sponsor
- All India Institute of Medical Sciences
Melanoma
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma
This study is being done to see if the investigators can help the immune system to work against melanoma. A dendritic cell is another type of white blood cell.
- Trial name
- NCT01456104
- Testing
- Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.